Researchers question efficacy of approved koala chlamydia vaccine
A molecular virologist has challenged a study claiming a single-dose vaccine reduced chlamydia deaths in koalas by 64 percent over 10 years.

Professor Keith Chappell, a molecular virologist at the University of Queensland, has questioned the efficacy of a chlamydia vaccine approved for koalas. He took issue with a 2024 paper published in npj Vaccines which stated the vaccine significantly lowered disease incidence and resulted in a 64% reduction in chlamydia deaths over a 10-year period.
The vaccine, which is available as a single-dose, was approved by the Australian Pesticides and Veterinary Medicines Authority in September 2025. Queensland researchers say the published study contains a 'silly mistake' that over-inflates the vaccine's efficacy, though the regulator is standing by its decision to approve it.
Chlamydia infection, caused most commonly by the bacterium Chlamydia pecorum, is a significant disease for the endangered marsupials. In some populations, the prevalence of chlamydia is as high as two in three. Infected females can become infertile quite rapidly, and heavily diseased animals can become emaciated.
Antibiotic treatment for koalas is difficult because the animals depend on gut microbes to digest toxic eucalypt leaves. Dr Lyndal Hulse, a postdoctoral research fellow at the University of Queensland, said antibiotics can cause a shift in the abundance of good microbes, leading to weight loss, diarrhoea, or fatal dysbiosis. Additionally, some chlamydia strains have developed antibiotic resistance.
At the Queensland University of Technology, Dr Freya Russell and her team are developing a two-dose vaccine using proteins from the outer membrane of chlamydia bacteria. To address the difficulty of catching wild koalas for a second shot, they developed a biodegradable, non-toxic implant that delivers the second dose over a few weeks.
The delayed-release implant is currently being trialled in wild koalas and has not yet been approved by the Australian Pesticides and Veterinary Medicines Authority. In captive studies at Currumbin, the implant showed the same efficacy as the two-shot vaccine in stimulating antibody responses.
Key facts
- A single-dose chlamydia vaccine for koalas was approved in September 2025.
- Professor Keith Chappell has questioned a study claiming the vaccine reduced chlamydia deaths by 64% over 10 years.
- Chlamydia prevalence in some koala populations is as high as two in three.
Three perspectives
Neutral
The Australian regulator is maintaining its approval of a koala chlamydia vaccine despite researcher claims of errors in efficacy studies.
Positive
Researchers have developed a biodegradable implant to help deliver a second vaccine dose to wild koalas.
Negative
Some researchers argue that a published study over-inflates the efficacy of an approved vaccine through a 'silly mistake'.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.